GlassScriptPhysician profile
Lela M Emad
NPI 1811902612
$6,379.83
in general payments reported to CMS, 2019-2025
43 companies · $852 in 2025
The $852 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $708 · 2021: $1,049 · 2022: $1,054 · 2023: $905 · 2024: $1,082 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,612.85 |
| Education | $225.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,133.98 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $736.39 | 2021-2025 | |
| Hologic Sales and Service, LLC | $646.34 | 2019-2025 | Myosure Tissue Removal Device, Acessa Provu System, Fluent Fluid Management System |
| Astellas Pharma US INC | $626.20 | 2020-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $468.96 | 2019-2022 | |
| Organon LLC | $382.33 | 2021-2025 | Nexplanon |
| Pfizer INC. | $293.84 | 2019-2024 | |
| Amag Pharmaceuticals, INC. | $260.05 | 2019-2021 | |
| Allergan, INC. | $146.65 | 2019-2022 | |
| Amgen INC. | $142.47 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $118.74 | 2021 | |
| Biogen, INC. | $115.62 | 2025 | Zurzuvae |
| Myovant Sciences INC. | $111.42 | 2021-2022 | |
| Avion Pharmaceuticals | $99.80 | 2019-2022 | |
| Evofem Biosciences, INC. | $96.21 | 2021-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lela Emad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.